Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)

被引:104
|
作者
Yu, Roger J. [1 ]
Krantz, Matthew S. [2 ]
Phillips, Elizabeth J. [1 ]
Stone, Cosby A., Jr. [2 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA
基金
美国国家卫生研究院;
关键词
FDA; FAERS; Anaphylaxis; Drug allergy; Death; Fatal;
D O I
10.1016/j.jaip.2020.09.021
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
BACKGROUND: Drug-induced anaphylaxis is a well-known adverse drug reaction for some drug classes, but emerging drug causes of anaphylaxis and novel mechanisms may contribute in unrecognized ways. OBJECTIVE: We sought to determine the top drugs reported in association with anaphylaxis and anaphylaxis followed by death in the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We reviewed the publicly available FAERS database from 1999 to 2019. Using search terms "anaphylactic shock" or "anaphylactic reaction" and sorting cases by generic drug names, we counted and trended reports to FAERS in which a drug was associated with anaphylaxis or anaphylaxis followed by death. RESULTS: From 1999 to 2019, there were 17,506,002 adverse drug events reported in FAERS, of which 47,496 (0.27%) were reported as anaphylaxis. Excluding patients without age, sex, or country data, respectively, the median age of patients in reports of anaphylaxis was 52 (interquartile range: 28), 62.71% were female, and 13,899 of 34,381 (40.43%) reports were from the United States. There were 2984 of 47,496 (6.28%) reports of anaphylaxis followed by death. Top drug classes associated with anaphylaxis in FAERS were antibiotics, monoclonal antibodies (mAbs), nonsteroidal anti-inflammatory drugs, and acetaminophen. Top drug classes associated with anaphylaxis deaths were antibiotics, radiocontrast agents, and intraoperative agents. Linear regression demonstrated reports of anaphylaxis to mAbs increasing at an average rate of 0.77% of total anaphylaxis reports per year (95% confidence interval: 0.65, 0.88) from 2.00% in 1999 to 17.37% in 2019, faster than any other drug class. CONCLUSION: Antibiotics were highly reported for anaphylaxis overall and anaphylaxis followed by death. Increasing reports were noted for anaphylaxis to mAb therapies. (C) 2020 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:819 / +
页数:13
相关论文
共 50 条
  • [21] Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System
    Wen, Xiao
    Cai, Le
    Gao, Ao
    Fu, An
    Guo, Daihong
    Zhu, Man
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025,
  • [22] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [23] Medication overdose data analysis: a review of medication error reports in the FDA adverse event reporting system (FAERS)
    Jiaqi Ni
    Xinru Tang
    Li Chen
    BMC Pharmacology and Toxicology, 24
  • [24] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [25] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [26] Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority
    Inês Ribeiro-Vaz
    Joana Marques
    Pascal Demoly
    Jorge Polónia
    Eva Rebelo Gomes
    European Journal of Clinical Pharmacology, 2013, 69 : 673 - 681
  • [27] Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority
    Ribeiro-Vaz, Ines
    Marques, Joana
    Demoly, Pascal
    Polonia, Jorge
    Gomes, Eva Rebelo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) : 673 - 681
  • [28] Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system
    Li, Wenwen
    Liu, Cuncheng
    Zhang, Zhongyi
    Cai, Zhikai
    Lv, Tailong
    Zhang, Ruiyuan
    Zuo, Yaoyao
    Chen, Shouqiang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [30] Carfiilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)
    Buck, Benjamin
    Kellett, Eric
    Addison, Daniel
    Vallakati, Ajay
    JOURNAL OF THE SAUDI HEART ASSOCIATION, 2022, 34 (03) : 134 - 141